Genes associated with ETV4-fusion-positive prostate cancers were used as the input, and four therapeutic candidate targets, PARP1, NQO1, HSPA5, and TOP1, and the respective selective drugs, olaparib, amrubicin, fluorouracil, and irinotecan, were identified. The gene discussed is NQO1; the disease is Familial prostate cancer.